Updated 13 January 2023: Please note that this initiative is no longer accepting applications.
Funding is being made available to help local health systems deploy innovative ideas and solutions which overcome barriers to the use of NICE-endorsed lipid management pathways.
To find out how we can support your organisation’s application to the System Transformation Fund, contact Nick Pringle at [email protected].
The following criteria must be met for an application to be considered:
The STF is a total award of up to £2.5m across England. There is no upper or lower limit for funding for applications. Previous funding requests from similar opportunities were in the range of £40,000 to £180,000, however this is only indicative, and all applications will be considered in terms of factors such as complexity as well as proposed population reach as relates to the funding request.
Contracting and administration of the finances for the STF will be undertaken by Northeast and North Cumbria Academic Health Science Network (NENC AHSN) on behalf of the Accelerated Access Collaborative and Novartis. Successful applicants will be contacted by NENC AHSN to complete the contracting process and administer payments.
The timeline for the STF award process
To find out how we can support your organisation in your application to the System Transformation Fund, contact Nick Pringle at [email protected].
Join a webinar to find out more about the STF – 12 October 2022 10:00 – 11:00
NHS England reserves the right to moderate applications as a measure to ensure that there is a reasonable geographical spread of funding that takes account of ICSs with the highest levels of health inequalities, as well as the strongest applications. Novartis Pharmaceuticals UK Limited (“Novartis”) has provided the funding for the creation of the System Transformation Fund (“STF”) as part of a collaborative working project between NHS England and Novartis. Novartis has had (i) no input into the delivery or execution of the STF and (ii) no involvement in the identification and/or selection of the recipients of the STF. Ownership of this Application Guidance document is the responsibility of NHS England. Novartis has checked this document for factual accuracy against applicable codes and both parties are working within applicable codes.
Do you have a great idea that could make a positive health impact?Get involved